I'm LongbridgeAI, I can summarize articles.Sinocelltech's subsidiary, Sinocelltech Engineering Co., Ltd., recently received approval from the National Medical Products Administration to conduct clinical trials for its independently developed SCTT11 injection for thyroid eye disease. This product aims to meet the medical needs of patients with thyroid eye disease and has a differentiated competitive advantage
According to the Zhitong Finance APP, Sinocelltech (688520.SH) announced that its holding subsidiary, Sinocelltech Engineering Co., Ltd., has received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, allowing the company's independently developed product SCTT11 injection to conduct clinical trials for the indication of thyroid eye disease.
Currently, there is still a significant unmet medical need for patients with thyroid eye disease, and there is an urgent need to develop new therapeutic drugs. The SCTT11 product is a monoclonal antibody injection independently developed by the company with the goal of differentiated competitive advantage for the treatment of thyroid eye disease